pf 4

Anti-CXCL4/PF4 Antibody is a humanized monoclonal antibody that binds specifically to the chemokine CXCL4 (PF4) with high affinity. By blocking its mediated biological effects and receptor interactions, it inhibits fibroblast activation and pro-inflammatory signaling. It serves as an important pharmacological tool for researching systemic sclerosis, thrombotic disorders, and inflammatory immune responses.

Platelet factor 4 (59-70) elicits human neutrophil & monocyte chemotaxis.

Anti-EFNA4 Antibody (PF-06647263 Naked Antibody) is a monoclonal antibody targeting EFNA4 and can be used for the synthesis of the ADC PF-06647263.

Highly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotrop

[Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 (Compound 3) is a copper complex known for suppressing cell viability in HCT116, HCT116DoxR, A2780, and fibroblasts, with IC50 values of 0.13, 0.15, 0.66, and 6.24 μM, respectively. It induces apoptosis and autophagy at the G0/G1 cell cycle phase and exhibits anti-metastatic properties.

(3S, 4S)-PF-06459988 is the less active S enantiomer of PF-06459988, a potent irreversible inhibitor of T790M mutant epidermal growth factor receptor (EGFR), exhibiting excellent selectivity against EGFR wild-type due to its minimally reactive electrophile, reducing off-target labeling likelihood.

(3S,4R)-PF-6683324 is a pro-myosin-related kinase (Trk) inhibitor with research potential for pain and cancer.

[(pF)Phe4]Nociceptin(1-13)NH2 acetate is a selective agonist of NOP receptor with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 acetate displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold).

Mp-4D7-pF2 is a cell-penetrating bicycle peptide that acts as a non-covalent inhibitor of the SARS-CoV-2 main protease (SARS-CoV-2 main protease) with an IC50 of 4.51 μM. It exhibits antiviral activity against SARS-CoV-2 without cytotoxicity and can be utilized in COVID-19 infection research.

casein kinase 1ε inhibitor

PF-429242 is a competitive inhibitor of sterol regulatory element-binding protein (SREBP) site 1 protease (IC50 = 0.175 μM). It is selective for site 1 protease against a panel of serine proteases. PF-429242 inhibits rate of cholesterol synthesis in CHO c

PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.

PF-4191834 is a noniron chelating and non-redox inhibitor of the 5-Lipoxygenase (5-LOX) with an IC50 of 229 nM. PF-4191834 shows ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX and displays no activity toward the cyclooxygenase enzymes. PF-4191834

PF-4981517 (CYP3cide) is a efficient, specific and time-dependent inhibitor of cytochrome P4503A4 (CYP3A4). The IC 50 values for CYP3A activity are 0.03 μM,17 μM, and 71 μM for CYP3A4, CYP3A5, and CYP3A7, respectively. PF-4981517 is able to be used to distinguish the contributions of CYP3A4 versus CYP3A5 on drug Metabolism.

PF-04822163 is a potent inhibitor of PDE1 with IC50 value of 0.0024 μM.

PF-4348235 HCl (β2AR/M-receptor agonist-2 HCl) is a muscarinic M3 receptor antagonist (Ki: 0.73 nM) and β2 adrenergic receptor agonist (MABA, EC50: 3.7 nM). PF-4348235 HCl is also a bronchial BM213 acetate is a bronchodilator used to study cardiovascular and respiratory diseases such as chronic obstructive pulmonary disease (COPD).

PF-4348235 2HCl is an adrenergic agonist and muscarinic receptor antagonist, a bronchodilator, and may be used in the study of chronic obstructive pulmonary disease.

PF429242 dihydrochloride is a reversible and competitive inhibitor of S1P, with an IC50 of 175 nM.

PF-4693627 is an effective and selective microsomal prostaglandin E synthase-1 inhibitor (IC50=3 nM). It is used for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA).

PF-4778574 is a positive AMPA receptor allosteric modulation (EC50: 45 to 919 nM in different cells).

PF-4878691 (3M-852A) is a potent and selective Toll-like receptor 7 agonist, designed to dissociate its antiviral and inflammatory activities.

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) .In cell-free assays, PF-4708671(PF4708671) is potent for S6K1(Ki50=20 nM, IC50=160 nM).

PF470 (PF-06297470) is a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5), which demonstrated significant therapeutic effects in Parkinson's disease models. However, its clinical development was halted due to potential issues identified in toxicological studies.

INCB10820 is an efficient and specific dual antagonist of CCR2 and CCR5, with oral bioavailability.